<DOC>
	<DOCNO>NCT02083965</DOCNO>
	<brief_summary>The primary objective study characterize pharmacokinetics ( PK ) rFVIIIFc administer vial strength 1000 3000 IU subject severe hemophilia A . The secondary objective study evaluate safety rFVIIIFc beyond PK assessment 6 month continue treatment period .</brief_summary>
	<brief_title>Pharmacokinetics rFVIIIFc Two Vial Strengths</brief_title>
	<detailed_description>This randomize , open-label , crossover study participant receive single injection rFVIIIFc 2 different vial concentration ( PK assessment ) . After PK assessment , participant provide rFVIIIFc either prophylactic episodic ( on-demand ) treatment 6 month .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Key Have severe hemophilia A Previously treat subject , define least 150 documented prior exposure day recombinant and/or plasmaderived FVIII and/or cryoprecipitate product ( use rFVIIIFc study drug commercial product ) Day 1 . Fresh frozen plasma treatment must consider count document exposure day . No history positive inhibitor test clinical sign decrease response FVIII administration . Family history inhibitor exclude subject . No measurable inhibitor activity use Nijmegenmodified Bethesda assay Screening . Platelet count ≥100,000 platelets/μL screen CD4 lymphocytes &gt; 200 mm3 know HIV antibody positive screening . Viral load &lt; 400 copies/mL know HIV antibody positive screening . Key Subject high risk bleed 5day period first second injection PK analysis , per Investigator discretion . Previous treatment rFVIIIFc study drug commercial product . Other coagulation disorder ( ) addition hemophilia A . History hypersensitivity anaphylaxis associate FVIII IV immunoglobulin administration . Currently take ( likely require study ) acetylsalicylic acid ( ASA ) , except lowdose ASA prophylaxis ( nonsteroidal antiinflammatory drug permit ) . Concurrent systemic treatment immunosuppressive drug within 12 week prior Day 1 . Exceptions include : ribavirin treatment hepatitis C virus ( HCV ) , and/or systemic steroid ( total 2 course pulse treatment last 7 day dose ≤1 mg/kg within 12 week prior Day 1 ) and/or inhaled steroid . NOTE : Other protocoldefined inclusion/exclusion Criteria May Apply</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>